Circulating Levels of Tissue Factor Microparticle Procoagulant Activity Are Reduced With Antiretroviral Therapy and Are Associated With Persistent Inflammation and Coagulation Activation Among HIV-Positive Patients

Baker, Jason V. MD, MS*,†; Huppler Hullsiek, Katherine PhD; Bradford, Robert L. BS§; Prosser, Rachel PhD, NP; Tracy, Russell P. PhD‖,¶; Key, Nigel S. MD§

JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e3182910121
Brief Report: Clinical Science
Abstract

Abstract: Activation of coagulation pathways may contribute to risk for non–AIDS-related conditions among HIV-positive patients. Tissue factor (TF)–dependent procoagulant activity on circulating microparticles (MP-TF) in the plasma of 163 HIV-positive participants, both untreated and treated, with viral suppression was measured. MP-TF activity was 39% lower among treated versus untreated participants (P < 0.001), which persisted in adjusted models (−36%, P = 0.03). Among treated participants, MP-TF activity correlated modestly with D-dimer (r = 0.24, P = 0.01), von Willebrand factor (r = 0.36, P < 0.001), and interleukin-6 (r = 0.20, P = 0.04) levels. Future research should focus on mechanisms driving residual functional TF activity and whether these alterations have clinical consequences for non–AIDS-defining complications.

Author Information

*Department of Medicine, University of Minnesota, Minneapolis, MN;

Department of Medicine, Hennepin County Medical Center, Minneapolis, MN;

Division of Biostatistics, University of Minnesota, Minneapolis, MN;

§Department of Medicine, University of North Carolina, Chapel Hill, NC;

Departments of Biochemistry; and

Pathology, University of Vermont, Burlington, VA.

Correspondence to: Jason V. Baker, MD, MS, Department of Medicine, Hennepin County Medical Center, 701 Park Avenue, Mail Code G5, Minneapolis, MN 55415 (e-mail: baker459@umn.edu).

Supported by NIH 1UL1RR033183, NIH 1KL2RR033182-01, NIH 5 K12 RR023247, AHA 09CRP2230357, and Gilead Pharmaceuticals.

The authors have no conflicts of interest to disclose.

Received January 14, 2013

Accepted March 05, 2013

© 2013 Lippincott Williams & Wilkins, Inc.